Unconfigured Ad
Collapse
Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc
| Forums | Topics | Posts | Last Post |
|---|
No forums found.
There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by laura, 05-09-2011, 04:42 AM
|
35 responses
107,575 views
0 reactions
|
Last Post
by laura
12-05-2013, 02:37 AM
|
||
|
Started by sci_guy, 01-23-2008, 11:19 PM
|
236 responses
684,026 views
1 reaction
|
Last Post
by ECO
12-25-2009, 06:45 PM
|
||
|
Started by lordjonwald, 11-17-2014, 09:13 AM
|
0 responses
1,905 views
0 reactions
|
Last Post
by lordjonwald
11-17-2014, 09:13 AM
|
||
|
Started by andrewm, 11-09-2014, 10:53 AM
|
5 responses
2,120 views
0 reactions
|
Last Post
by maubp
11-17-2014, 08:00 AM
|
||
|
Started by thh32, 11-17-2014, 03:59 AM
|
3 responses
3,348 views
0 reactions
|
Last Post
by GenoMax
11-17-2014, 06:39 AM
|
||
|
Started by blancha, 06-23-2014, 05:12 PM
|
4 responses
3,733 views
0 reactions
|
Last Post
by blancha
11-17-2014, 06:26 AM
|
||
|
Started by stephenj, 11-17-2014, 03:28 AM
|
0 responses
1,404 views
0 reactions
|
Last Post
by stephenj
11-17-2014, 03:28 AM
|
||
|
Started by heso, 11-16-2014, 04:14 AM
|
3 responses
14,054 views
0 reactions
|
Last Post
by heso
11-17-2014, 01:57 AM
|
||
|
Started by bob-loblaw, 01-15-2014, 02:07 AM
|
8 responses
3,899 views
0 reactions
|
Last Post
|
||
|
Started by Ashwini M, 11-16-2014, 10:59 PM
|
1 response
1,728 views
0 reactions
|
Last Post
by dpryan
11-17-2014, 12:55 AM
|
||
|
Started by balthasar, 11-16-2014, 05:46 PM
|
0 responses
1,577 views
0 reactions
|
Last Post
by balthasar
11-16-2014, 05:46 PM
|
||
|
Started by jrenart, 11-15-2014, 05:00 AM
|
2 responses
1,454 views
0 reactions
|
Last Post
by jrenart
11-16-2014, 03:10 AM
|
No topics found.
-
Page of 0
-
Filter
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
Recent Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
-
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
30 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
||
|
Started by SEQadmin2, 07-09-2026, 10:04 AM
|
0 responses
41 views
0 reactions
|
Last Post
by SEQadmin2
07-09-2026, 10:04 AM
|